Señales en vivo de GOSS | Maximiza tus Ganancias con Getagraph.com

VENDER 109374 min ago

@ $0.910

Emitido: 13 feb 2024 @ 14:52

Retorno: -21.98%

Señal anterior: feb 12 - 13:31

Señal anterior: Comprar

Retorno: 3.99 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 14:47):

Stats
Volumen de hoy	941 260
Volumen promedio	1.40M
Capitalización de mercado	160.62M
EPS	$0 ( 2024-03-15 )
Próxima fecha de ganancias	( $-0.190 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00300 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Christian Waage	Sell	6 430	Common Stock
2024-03-27	Giraudo Bryan	Sell	6 430	Common Stock
2024-03-27	Hasnain Faheem	Sell	23 172	Common Stock
2024-03-18	Aranda Richard	Sell	4 018	Common Stock
2024-03-18	Peterson Caryn	Sell	4 018	Common Stock

INSIDER POWER
76.16
Last 96 transactions
Buy: 11 435 031 \| Sell: 1 983 654

Volumen Correlación

Largo: 0.09 (neutral)

Corto: 0.15 (neutral)

Signal:(68.749) Neutral

Gossamer Bio Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gossamer Bio Inc Correlación - Moneda/Commodity

-0.57
( weak negative )

-0.78
( moderate negative )

0.00
( neutral )

0.69
( moderate )

0.71
( moderate )

Gossamer Bio Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-4.39M (0.00 %)
EPS:	$-1.180

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-4.39M (0.00 %)
EPS:	$-1.180

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-4.43M (0.00 %)
EPS:	$-2.84

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.